DelveInsight’s “Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Open Angle Glaucoma, historical and forecasted epidemiology as well as the Open Angle Glaucoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Get a Free sample for the Open Angle Glaucoma Market Report
https://www.delveinsight.com/report-store/open-angle-glaucoma-market
Some of the key facts of the Open Angle Glaucoma Market Report:
-
The Open Angle Glaucoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In June 2025, Qlaris Bio presented new data on its lead investigational compound, QLS-111, at the 2025 World Glaucoma Congress (WGC), including results from the Phase II 'Osprey' (QC-111-201) studies in patients with primary open-angle glaucoma (POAG) and ocular hypertension.
-
In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, announced that the final patient has completed their last visit in the Whistler Phase 3b trial evaluating NCX 470’s dual mechanism of action—nitric oxide and prostaglandin analog—for reducing intraocular pressure (IOP). NCX 470, Nicox’s lead clinical candidate, is an innovative NO-donating bimatoprost eye drop currently in Phase 3 development for treating open-angle glaucoma and ocular hypertension.
-
In February 2025, Qlaris Bio, Inc., a clinical-stage biotechnology company focused on addressing unmet needs in severe ophthalmic conditions, has reported positive topline results from two U.S. Phase II trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). The Phase II studies, Osprey and Apteryx, achieved all primary and secondary endpoints successfully.
-
In January 2025, Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceuticals and medical technologies for glaucoma treatment, has launched a Phase 2b/3 clinical program for iDose TREX, its next-generation sustained-release therapeutic platform. iDose TREX is designed to resemble the original iDose TR in size and shape but offers nearly double the drug capacity.
-
In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference in Chicago, Illinois, findings from a Phase II study on the safety of Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The study focused on neuroprotection in patients with glaucoma. Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University, shared the results, which demonstrated that CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported.
-
In the United States, around 80% of glaucoma cases are identified as OAG, making it the most common type of glaucoma in the country.
-
In the United States, more than 2.7 million people aged 40 and above are affected by glaucoma, highlighting its considerable public health impact.
-
In Europe, primary OAG affects approximately 7.8 million people, with an overall prevalence of 2.51%
-
Primary OAG is the most prevalent form of glaucoma in the UK, occurring in about 2% of people over age 40 and 10% of those over age 75.
-
Key Open Angle Glaucoma Companies: Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others
-
Key Open Angle Glaucoma Therapies: OMLONTI (omidenepag isopropyl ophthalmic solution), ZIOPTAN (tafluprost ophthalmic solution), Citicoline, PA5108, Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others
-
The Open Angle Glaucoma epidemiology based on gender analyzed that women are predominantly affected by Open Angle Glaucoma (OAG) in the 7MM
-
The Open Angle Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Open Angle Glaucoma pipeline products will significantly revolutionize the Open Angle Glaucoma market dynamics.
Open Angle Glaucoma Overview
Open-Angle Glaucoma is the most common type of glaucoma, characterized by a gradual increase in eye pressure (intraocular pressure) due to slow clogging of the drainage canals. This leads to optic nerve damage and progressive, irreversible vision loss, often starting with peripheral vision. It is called "open-angle" because the angle between the iris and cornea remains open, but the drainage system is partially blocked. Often asymptomatic in early stages, it is known as the "silent thief of sight." Early detection through regular eye exams and treatment with eye drops, oral medications, laser therapy, or surgery can help manage the condition.
To Know in detail about the Open Angle Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Open Angle Glaucoma Market Forecast
Open Angle Glaucoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Open Angle Glaucoma Epidemiology Segmentation:
The Open Angle Glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalent Cases of Glaucoma in the 7MM
-
Total Diagnosed Prevalent Cases Glaucoma in the 7MM
-
Type-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM
-
Type-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM
-
Gender-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM
-
Age-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM
Download the report to understand which factors are driving Open Angle Glaucoma epidemiology trends @ Open Angle Glaucoma Epidemiology Forecast
Open Angle Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open Angle Glaucoma market or expected to get launched during the study period. The analysis covers Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Open Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Open Angle Glaucoma Therapies and Key Companies
-
OMLONTI (omidenepag isopropyl ophthalmic solution): Ocuvex Therapeutics
-
ZIOPTAN (tafluprost ophthalmic solution): Thea Pharma
-
PA5108: PolyActiva Pty
-
NCX-470: Nicox Ophthalmics
-
PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma
-
TC-002 (latanoprost): TearClear
-
iDose TR (Travoprost Intraocular Implant): Glaukos Corporation
-
Sepetaprost/DE-126/ONO-9054/STN-1012600: Santen Inc/Ono Pharmaceutical
-
Catioprost/DE-130A/STN1013001: Santen Pharmaceuticals
-
Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain
-
H-1337: D. Western Therapeutics Institute (DWTI)
-
OTX-TIC: Ocular Therapeutix, Inc.
-
LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)
-
TRS01: Tarsier Pharma
-
POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic
-
Nyxol (Phentolamine Mesylate): Ocuphire Pharma
-
QLS-101: Qlaris Bio, Inc.
-
BTQ-1902: Betaliq, Inc.
-
VVN539: VivaVision Biotech, Inc.
-
AGN-193408: Abbvie
Discover more about therapies set to grab major Open Angle Glaucoma market share @ Open Angle Glaucoma Treatment Market
Open Angle Glaucoma Market Strengths
-
Rising prevalence of Open Angle Glaucoma (OAG) resulting in demand for improved treatments. Growing awareness about the importance of early detection to reduce the disease burden contributes to increased screening and diagnosis rates
Open Angle Glaucoma Market Opportunities
-
With increasing awareness and improving healthcare infrastructure, the Open Angle Glaucoma (OAG) market has growth potential in emerging markets
Scope of the Open Angle Glaucoma Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Open Angle Glaucoma Companies: Ocuvex Therapeutics, Thea Pharma, Omikron Italia, PolyActiva Pty, OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others
-
Key Open Angle Glaucoma Therapies: OMLONTI (omidenepag isopropyl ophthalmic solution), ZIOPTAN (tafluprost ophthalmic solution), Citicoline, PA5108, Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others
-
Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies
-
Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Open Angle Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Open Angle Glaucoma Market Access and Reimbursement
To know more about Open Angle Glaucoma companies working in the treatment market, visit @ Open Angle Glaucoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Open Angle Glaucoma Market Report Introduction
2. Executive Summary for Open Angle Glaucoma
3. SWOT analysis of Open Angle Glaucoma
4. Open Angle Glaucoma Patient Share (%) Overview at a Glance
5. Open Angle Glaucoma Market Overview at a Glance
6. Open Angle Glaucoma Disease Background and Overview
7. Open Angle Glaucoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Open Angle Glaucoma
9. Open Angle Glaucoma Current Treatment and Medical Practices
10. Open Angle Glaucoma Unmet Needs
11. Open Angle Glaucoma Emerging Therapies
12. Open Angle Glaucoma Market Outlook
13. Country-Wise Open Angle Glaucoma Market Analysis (2020–2034)
14. Open Angle Glaucoma Market Access and Reimbursement of Therapies
15. Open Angle Glaucoma Market Drivers
16. Open Angle Glaucoma Market Barriers
17. Open Angle Glaucoma Appendix
18. Open Angle Glaucoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
